KYMR vs. RVMD: Kymera Therapeutics vs. Revolution Medicines Stock Comparison

November 11, 2026

How do Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Profile Item	KYMR	RVMD
Name	Kymera Therapeutics Inc.	Revolution Medicines, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	11.25 billion USD	41.59 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 21, 2020	February 13, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

KYMR

RVMD

GSPC

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Total Return (1Y)	131.52%	224.80%
Total Return (3Y, Annualized)	111.65%	114.71%
Total Return (5Y, Annualized)	15.68%	43.47%

Risk Profile

Drawdown History

KYMR

RVMD

GSPC

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Volatility (1Y, Annualized)	62.83%	68.29%
Beta (5Y)	2.00	1.42
Max Drawdown (5Y)	-83.27%	-55.71%
Avg. Volume (3M)	833.05K	2.06M

Risk-Adjusted Performance

Risk-Return Positioning

KYMR and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Sharpe Ratio (1Y)	2.03	3.23
Sortino Ratio (1Y)	4.16	6.92

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Revolution Medicines (RVMD) at -93.56% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
RVMD: -93.56%
Min: -167.77%

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Kymera Therapeutics (KYMR) at 0.00% and Revolution Medicines (RVMD) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
RVMD: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Kymera Therapeutics (KYMR) at -396.04% and Revolution Medicines (RVMD) at -188.88% report negative operating margin values, usually indicating operating losses over the period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
RVMD: -188.88%
Min: -207.40%

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
ROE (TTM)	-27.29%	-93.56%
ROA (TTM)	-17.64%	-32.13%
Net Margin (TTM)	0.00%	0.00%
Operating Margin (TTM)	-396.04%	-188.88%
Gross Margin (TTM)	0.00%	0.00%

Growth

Revenue Growth

Only one side can be read here: Kymera Therapeutics (KYMR) reports revenue growth of -16.70%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Revenue Growth (YoY)	-16.70%	--
Revenue Growth (3Y CAGR)	-5.74%	--
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 11.13 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max: 25.13
Q3: 12.13
RVMD: 8.36
Median: 5.52
Q1: 2.47
Min: 0.10

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max: 1.42
Q3: 0.65
RVMD: 0.50
Median: 0.15
Q1: 0.02
Min: 0.00

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Current Ratio (MRQ)	11.13	8.36
Debt / Equity (MRQ)	0.05	0.50
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Revolution Medicines (RVMD) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RVMD: --

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Investors are paying well above the peer range per dollar of sales for both Kymera Therapeutics (KYMR) at 110.00 and Revolution Medicines (RVMD) at 210.51 — each P/S ratio clears its industry’s benchmark range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD: 210.51
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD: 17.31
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Kymera Therapeutics (KYMR) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Revolution Medicines (RVMD)
Metric	KYMR	RVMD
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	110.00	210.51
P/B Ratio (MRQ)	6.96	17.31
Free Cash Flow Yield (TTM)	-1.46%	-2.13%